TLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Telix Pharmaceuticals Ltd (TLX) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the technical indicators show bullish trends, the lack of recent news, financial performance data, and no significant trading trends from insiders or hedge funds make it difficult to justify an immediate investment. Additionally, the AI Stock Picker and SwingMax signals are absent, and the stock's short-term trend indicates potential volatility. For a long-term investor, it may be better to monitor the stock for further developments, particularly regulatory catalysts and financial updates.
The MACD is positive and expanding, indicating bullish momentum. The RSI is at 76.447, which is neutral but leaning towards overbought territory. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading above key resistance levels (R1: 10.004, R2: 10.228). However, the stock has a 60% chance of declining by -10.45% in the next week, suggesting potential short-term downside.
Analysts from JPMorgan have initiated coverage with an Overweight rating and a price target of A$23.60, citing structural tailwinds in radioligand therapies and upcoming regulatory catalysts such as FDA clearance for TLX-591 and Pixclara approval.
No significant trading trends from hedge funds or insiders. No recent news or congress trading data. Short-term stock trend analysis indicates a potential decline in the next week (-10.45%).
No financial data available for analysis.
JPMorgan has given an Overweight rating with a price target of A$23.60, highlighting structural tailwinds and upcoming regulatory catalysts. No recent changes in analyst ratings or price targets.
